NEW YORK (AP) -- Seattle Genetics said Wednesday it expanded a cancer treatment collaboration with drugmaker AbbVie.
The Bothell, Wash., company said it will receive a $25 million upfront payment from AbbVie, and it could get $255 million in license and milestones payment per drug. AbbVie also agreed to pay Seattle Genetics royalties in the single digits on sales of any drugs that are approved.
Seattle Genetics Inc. and Abbott Laboratories started working together in March 2011 on experimental antibodies designed to fight cancer. The antibodies are designed to selectively deliver anticancer drugs to tumor cells. Abbott made an $8 million upfront payment. In October 2012 the companies agreed to expand their partnership, and Abbott paid Seattle Genetics another $25 million.
AbbVie was spun off from Abbott a year ago. It sells branded prescription drugs, including the blockbuster anti-inflammatory drug Humira, which is used to treat rheumatoid arthritis, psoriasis and Crohn's disease.
The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Delayed Retirement Credits: What They Are and Why They're Getting Harder to Earn
Is there a threat to this key way to boost your Social Security benefits?
4 Ways to Save on Healthcare in 2018
Healthcare in the U.S. is shockingly expensive, and prices are only rising. Luckily, these healthcare hacks can reduce your own medical expenses.
GM Proved Doubters Wrong in 2017 With a Strong Crossover Lineup
GM surprised the market when it announced strong guidance thanks to a revamped line of crossovers and SUVs. Better still, it delivered on the promises.